Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Maze Therapeutics, Inc. (MAZE) had Stock-Based Compensation of $7.11M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$20.00M |
|
$-24.21M |
|
-- |
|
$20.00M |
|
$46.55M |
|
$-26.55M |
|
$2.35M |
|
$-24.21M |
|
$-24.21M |
|
$-24.21M |
|
$-24.21M |
|
$-24.21M |
|
$-24.21M |
|
$-26.55M |
|
$-25.74M |
|
53.90M |
|
53.90M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$379.78M |
|
$4.68M |
|
$39.93M |
|
$419.71M |
|
$21.24M |
|
$38.83M |
|
$56.77M |
|
$78.01M |
|
$341.70M |
|
$341.70M |
|
$341.70M |
|
49.74M |
|
| Cash Flow Statement Financials | |
$-39.11M |
|
$6.28M |
|
$42.36M |
|
$190.34M |
|
$199.85M |
|
$9.52M |
|
|
Stock-Based Compensation |
$7.11M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.88 |
|
-- |
|
-- |
|
0.10 |
|
0.11 |
|
100.00% |
|
-132.76% |
|
-132.76% |
|
-- |
|
-121.04% |
|
-121.04% |
|
$-39.21M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
1.00 |
|
90.00 |
|
-7.08% |
|
-7.08% |
|
-5.77% |
|
-6.36% |
|
$6.87 |
|
$-0.73 |
|
$-0.73 |
|